The release of promising clinical trial data has significantly impacted the after-hour stock value of Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) on Tuesday. EPRX stock price surged by 37.85%, reaching $3.97 at the last check.
Promising Clinical Data
Further encouraging results from the Phase 1b/2a RESOLVE study, which evaluates the safety and effectiveness of EP-104GI in the treatment of eosinophilic esophagitis (EoE), were revealed by Eupraxia (EPRX). Fresh information from the RESOLVE trial’s first and second cohorts showed satisfactory tolerance and persistent indications of possible benefit for up to 24 weeks without appreciable adverse effects.
Additionally, preliminary data from the third cohort revealed improvements in patient-reported symptoms and histological outcomes at the 12-week mark. Overall, Eupraxia is observing an increasing volume of favorable data while maintaining a robust safety profile.
Future Data Releases And Findings
Eupraxia plans to continue periodically releasing additional data from the RESOLVE trial. The latest results, derived from lower doses of four to eight 1 mg injections of EP-104GI administered to the lower esophagus of each patient, highlighted several key findings:
- Mild to moderate treatment-emergent adverse events, likely unrelated to EP-104GI, were observed with ongoing dose escalation.
- The first and second cohorts maintained signs of potential efficacy, with symptom improvements persisting up to 24 weeks.
- Reductions in Peak Eosinophil Counts (PEC) and Eosinophilic Esophagitis Histology Scoring System (EoEHSS) scores were noted in all second cohort patients at 12 weeks.
The data suggests the possibility of extending intervals between intra-esophageal injections, with potential further extensions at higher doses.
Previous And Recent Data Insights
Eupraxia had previously announced findings from the RESOLVE trial on February 5, 2024. The recent data release includes objective EoEHSS results and positive patient symptom scores at the 24-week mark. Notably, reductions in PEC and EoEHSS scores were observed in the two evaluable patients from the third cohort at 12 weeks, with one of the three enrolled patients found not to have eosinophils after joining the trial.
Eupraxia Pharmaceuticals continues to demonstrate progress in its clinical trials, contributing to significant stock value growth and promising advancements in treating eosinophilic esophagitis.
